Policy / Pricing Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care Drug ChannelsBy Bryce Platt, PharmD Minnesota's new 340B data reveal a growing disconnect between the program's size and the value Minnesotans receive in return.Policy / PricingRead full story pharminent April 23, 2026 (Last updated: April 23, 2026) Drug Channels By Bryce Platt, PharmD Minnesota’s new 340B data reveal a growing disconnect between the program’s size and the value Minnesotans receive in return. Policy / PricingRead full story Post navigation Previous: Sanofi receives FDA approval for Tzield in paediatric diabetesNext: AAN 2026: J&J, Kyverna, Capricor and Praxis showcase practice-changing data Related Stories Policy / Pricing Mid-cap biotechs join Trump’s latest round of drug pricing deals pharminent September 1, 2026 Policy / Pricing MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones pharminent August 27, 2026 Policy / Pricing MFN affecting Swiss medicines access, says Interpharma pharminent August 13, 2026